Robert Hazlett
Stock Analyst at BTIG
(0.66)
# 3,718
Out of 4,711 analysts
25
Total ratings
34.38%
Success rate
-18.28%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $8.20 | +192.68% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.93 | +330.90% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.40 | +900.00% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.18 | +11,011.11% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $90.73 | +8.01% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $4.19 | +1,331.98% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.97 | +1,486.90% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $15.22 | +90.54% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $83.45 | -52.07% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $6.50 | +399,900.00% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $1.83 | +227.87% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $27 | $8.36 | +222.97% | 2 | Oct 16, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $8.20
Upside: +192.68%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.93
Upside: +330.90%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.40
Upside: +900.00%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.18
Upside: +11,011.11%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $90.73
Upside: +8.01%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $4.19
Upside: +1,331.98%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.97
Upside: +1,486.90%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $15.22
Upside: +90.54%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $83.45
Upside: -52.07%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $6.50
Upside: +399,900.00%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.83
Upside: +227.87%
Oct 16, 2017
Maintains: Buy
Price Target: $18 → $27
Current: $8.36
Upside: +222.97%